['super-refractory status epilepticus']
['sage-547']

        Inclusion Criteria:

          -  Subjects 2 years of age and older.

          -  Subjects with an EEG-confirmed SRSE diagnosis under concomitant therapy with a
             continuous IV AED (third-line agent) for ≥ 24 hours. For this study, SRSE is defined
             by the following criteria and in accordance with those used at major epilepsy
             treatment centers:

               -  Failure to respond to the administration of at least one first-line agent (e.g.,
                  benzodiazepine or other emergent initial AED treatment), according to institution
                  standard of care, and

               -  Failure to respond to at least one second-line agent (e.g., phenytoin,
                  fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control
                  AED) according to institution standard of care, and

               -  Presence of one or more breakthrough seizures > 6 hours after initiation of the
                  continuous IV AED/third-line agent (e.g., pentobarbital, midazolam, propofol)

        Exclusion Criteria:

          -  Subjects with SRSE due to anoxic/hypoxic encephalopathy, children (subjects aged less
             than 18 years) with an encephalopathy due to an underlying progressive neurological
             disorder.

          -  Subjects with clinically significant electrocardiogram (ECG) abnormalities.

          -  Subjects with a significant medical or surgical condition that may compromise vital
             organ systems, or other conditions that would place the subject at increased risk such
             as dialysis or acute respiratory distress syndrome, severe cardiogenic or vasodilatory
             shock requiring 2 or more pressors, fulminant hepatic failure, etc.

          -  Subjects who are receiving a continuous IV AED (third-line agent) for seizure
             suppression or burst-suppression that will require greater than 24 hours to wean.
      